Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Lancet
J L MegaM S Sabatine

Abstract

Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy. A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis. When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was show...Continue Reading

References

Apr 14, 1994·The New England Journal of Medicine·M E MarenbergU de Faire
Sep 23, 2003·European Heart Journal·Shu YeChristopher N Martyn
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen
Jan 29, 2008·Journal of the American College of Cardiology·Olga A IakoubovaEugene Braunwald
Mar 21, 2008·The New England Journal of Medicine·Sekar KathiresanMarju Orho-Melander
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Mar 11, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Olga A IakoubovaJames Shepherd
Jan 12, 2012·Circulation. Cardiovascular Genetics·George ThanassoulisChristopher J O'Donnell
Mar 20, 2012·Cell·Sekar Kathiresan, Deepak Srivastava
Oct 27, 2012·European Heart Journal·Jemma C HopewellUNKNOWN MRC/BHF Heart Protection Study Collaborative Group
Jul 6, 2013·European Heart Journal·Vinicius TraganteUNKNOWN SMART study group
Jul 9, 2013·European Heart Journal·Ulrich LaufsChris J Packard

❮ Previous
Next ❯

Citations

Oct 18, 2015·European Heart Journal·Heribert Schunkert
Jan 5, 2016·European Heart Journal·M John ChapmanUlf Landmesser
Jan 29, 2016·Atherosclerosis·Zi YeIftikhar J Kullo
Dec 25, 2015·JACC. Cardiovascular Imaging·Harvey S HechtY Chandrashekhar
Apr 15, 2015·Journal of Molecular and Cellular Cardiology·J Gustav Smith, Christopher Newton-Cheh
Nov 27, 2015·Pharmacogenomics·Li-Shiun ChenLaura J Bierut
Oct 23, 2015·Future Cardiology·James MacNamaraLaurence Sperling
Jan 19, 2016·Current Opinion in Lipidology·Chris J Packard, Ian Ford
Sep 26, 2015·Journal of the American College of Cardiology·Steven R Steinhubl, Eric J Topol
Jun 20, 2015·Journal of the American College of Cardiology·Robert P Giugliano, Marc S Sabatine
Nov 10, 2015·British Journal of Clinical Pharmacology·Ammar KurdiWim Martinet
Apr 12, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Philippe Gabriel Steg, Grégory Ducrocq
Mar 10, 2015·Lancet·Heribert Schunkert, Nilesh J Samani
May 22, 2016·Journal of Clinical Lipidology·William Virgil BrownSekar Kathiresan
May 4, 2016·Nature Reviews. Genetics·Nilanjan ChatterjeeMontserrat García-Closas
May 28, 2016·Journal of the American College of Cardiology·Panagiotis AntiochosPeter Vollenweider
Jun 29, 2016·Atherosclerosis·Osman Najam, Kausik K Ray
Sep 23, 2016·European Heart Journal·Gad AbrahamMichael Inouye
Nov 5, 2016·Pharmacogenomics·Fannie MottetSimon de Denus
Jul 2, 2016·Heart·Richard W MorrisUNKNOWN UCLEB Consortium
Feb 17, 2017·Current Opinion in Lipidology·Themistocles L AssimesLiana C Del Gobbo
Mar 3, 2017·Journal of Atherosclerosis and Thrombosis·Hayato TadaMasakazu Yamagishi
May 10, 2017·Antioxidants & Redox Signaling·Sylvia DaunertPascal J Goldschmidt-Clermont
Apr 8, 2017·Mayo Clinic Proceedings·John R GiudicessiMichael J Ackerman
Jun 18, 2017·Revista Española De Cardiología·Roberto Elosua, Sergi Sayols-Baixeras
Feb 27, 2018·Nature Reviews. Genetics·Konrad J Karczewski, Michael P Snyder
Feb 3, 2018·Annals of Neurology·Chin Hong Tan, Rahul S Desikan
Mar 24, 2018·Pharmacogenomics·Kevin A Friede, Deepak Voora
Jan 11, 2018·Current Opinion in Cardiology·Robert Roberts
Apr 5, 2018·Cardiovascular Research·Jeanette ErdmannHeribert Schunkert
Jul 14, 2018·Clinical Pharmacology and Therapeutics·Patrick A Field, Ramachandran S Vasan
Jul 7, 2018·Current Opinion in Cardiology·Robert Roberts, Arlene Campillo
Apr 12, 2018·Annual Review of Genomics and Human Genetics·Daniel M Jordan, Ron Do

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.